• TOCILIZUMAB CHEMBL1237022 FDA ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    MRA
    Roactemra
    Tocilizumab
    Atlizumab
    RG-1569
    RHPM-1
    R-1569
    Actemra Roactemra
    Actemra
    2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXY-ETHOXY)BENZAMIDE
    DB08208
    AMNKRBRQQAMACZ-UHFFFAOYSA-N
    SCHEMBL5990623
    10150081
    2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
    TOCILIZUMAB (GENETICAL RECOMBINATION) (JAN)
    TOCILIZUMAB (GENETICAL RECOMBINATION)
    TOCILIZUMAB (USAN/INN)
    ACTEMRA (TN)
    375823-41-9
    D02596
    DAP001448
    17396767
    178103463
    6881
    RoActemra®
    DB06273

    Drug Info:

    Drug Class immunosuppressive agent
    Year of Approval 2010
    FDA Approval Rheumatoid arthritis, Juvenile idiopathic arthritis
    Drug Class Immunotherapies
    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antiinflammatory agent,DMARD
    Drug Categories serum globulins
    Drug Categories proteins
    Drug Categories interleukin inhibitors
    Drug Categories immunosuppressive agents
    Drug Categories immunoproteins
    Drug Categories immunoglobulins
    Drug Categories globulins
    Drug Categories blood proteins
    Drug Categories biologics for rheumatoid arthritis treatment
    Drug Categories antineoplastic and immunomodulating agents
    Drug Categories antibodies, monoclonal
    Drug Categories antibodies
    Drug Categories amino acids, peptides, and proteins
    Drug Groups approved
    Drug Type biotech
    Drug Categories N/A
    Drug Groups experimental
    Drug Type small molecule
    (5 More Sources)